[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Chronic Myelogenous Leukemia Treatment Market Report 2017

December 2017 | 97 pages | ID: U08F8C58BEBEN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the United States Chronic Myelogenous Leukemia Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
  • The West
  • Southwest
  • The Middle Atlantic
  • New England
  • The South
  • The Midwest
  • with sales (volume), revenue (value), market share and growth rate of Chronic Myelogenous Leukemia Treatment in these regions, from 2012 to 2022 (forecast).
United States Chronic Myelogenous Leukemia Treatment market competition by top manufacturers/players, with Chronic Myelogenous Leukemia Treatment sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
  • Bristol-Myers Squibb
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceuticals
  • Roche Holdings AG
  • Incyte Corporation
  • Bio-Path Holdings
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
  • Disease Specific Treatment
  • Symptomatic Treatment
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies
If you have any special requirements, please let us know and we will offer you the report as you want.
United States Chronic Myelogenous Leukemia Treatment Market Report 2017

1 CHRONIC MYELOGENOUS LEUKEMIA TREATMENT OVERVIEW

1.1 Product Overview and Scope of Chronic Myelogenous Leukemia Treatment
1.2 Classification of Chronic Myelogenous Leukemia Treatment by Product Category
  1.2.1 United States Chronic Myelogenous Leukemia Treatment Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Chronic Myelogenous Leukemia Treatment Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Disease Specific Treatment
  1.2.4 Symptomatic Treatment
1.3 United States Chronic Myelogenous Leukemia Treatment Market by Application/End Users
  1.3.1 United States Chronic Myelogenous Leukemia Treatment Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Hospital Pharmacies
  1.3.3 Specialty Pharmacies
  1.3.4 Retail Pharmacies
1.4 United States Chronic Myelogenous Leukemia Treatment Market by Region
  1.4.1 United States Chronic Myelogenous Leukemia Treatment Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Chronic Myelogenous Leukemia Treatment Status and Prospect (2012-2022)
  1.4.3 Southwest Chronic Myelogenous Leukemia Treatment Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Chronic Myelogenous Leukemia Treatment Status and Prospect (2012-2022)
  1.4.5 New England Chronic Myelogenous Leukemia Treatment Status and Prospect (2012-2022)
  1.4.6 The South Chronic Myelogenous Leukemia Treatment Status and Prospect (2012-2022)
  1.4.7 The Midwest Chronic Myelogenous Leukemia Treatment Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Chronic Myelogenous Leukemia Treatment (2012-2022)
  1.5.1 United States Chronic Myelogenous Leukemia Treatment Sales and Growth Rate (2012-2022)
  1.5.2 United States Chronic Myelogenous Leukemia Treatment Revenue and Growth Rate (2012-2022)

2 UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA TREATMENT MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Chronic Myelogenous Leukemia Treatment Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Chronic Myelogenous Leukemia Treatment Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Chronic Myelogenous Leukemia Treatment Average Price by Players/Suppliers (2012-2017)
2.4 United States Chronic Myelogenous Leukemia Treatment Market Competitive Situation and Trends
  2.4.1 United States Chronic Myelogenous Leukemia Treatment Market Concentration Rate
  2.4.2 United States Chronic Myelogenous Leukemia Treatment Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Chronic Myelogenous Leukemia Treatment Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA TREATMENT SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Chronic Myelogenous Leukemia Treatment Sales and Market Share by Region (2012-2017)
3.2 United States Chronic Myelogenous Leukemia Treatment Revenue and Market Share by Region (2012-2017)
3.3 United States Chronic Myelogenous Leukemia Treatment Price by Region (2012-2017)

4 UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA TREATMENT SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Chronic Myelogenous Leukemia Treatment Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Chronic Myelogenous Leukemia Treatment Revenue and Market Share by Type (2012-2017)
4.3 United States Chronic Myelogenous Leukemia Treatment Price by Type (2012-2017)
4.4 United States Chronic Myelogenous Leukemia Treatment Sales Growth Rate by Type (2012-2017)

5 UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA TREATMENT SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Chronic Myelogenous Leukemia Treatment Sales and Market Share by Application (2012-2017)
5.2 United States Chronic Myelogenous Leukemia Treatment Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA TREATMENT PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Bristol-Myers Squibb
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Chronic Myelogenous Leukemia Treatment Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Novartis AG
  6.2.2 Chronic Myelogenous Leukemia Treatment Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Novartis AG Chronic Myelogenous Leukemia Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Pfizer Inc.
  6.3.2 Chronic Myelogenous Leukemia Treatment Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Pfizer Inc. Chronic Myelogenous Leukemia Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Teva Pharmaceuticals
  6.4.2 Chronic Myelogenous Leukemia Treatment Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Roche Holdings AG
  6.5.2 Chronic Myelogenous Leukemia Treatment Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Roche Holdings AG Chronic Myelogenous Leukemia Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Incyte Corporation
  6.6.2 Chronic Myelogenous Leukemia Treatment Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Incyte Corporation Chronic Myelogenous Leukemia Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Bio-Path Holdings
  6.7.2 Chronic Myelogenous Leukemia Treatment Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview

7 CHRONIC MYELOGENOUS LEUKEMIA TREATMENT MANUFACTURING COST ANALYSIS

7.1 Chronic Myelogenous Leukemia Treatment Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Chronic Myelogenous Leukemia Treatment

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Chronic Myelogenous Leukemia Treatment Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Chronic Myelogenous Leukemia Treatment Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA TREATMENT MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Chronic Myelogenous Leukemia Treatment Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Chronic Myelogenous Leukemia Treatment Sales Volume Forecast by Type (2017-2022)
11.3 United States Chronic Myelogenous Leukemia Treatment Sales Volume Forecast by Application (2017-2022)
11.4 United States Chronic Myelogenous Leukemia Treatment Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Product Picture of Chronic Myelogenous Leukemia Treatment
Figure United States Chronic Myelogenous Leukemia Treatment Market Size () by Type (2012-2022)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Volume Market Share by Type (Product Category) in 2016
Figure Disease Specific Treatment Product Picture
Figure Symptomatic Treatment Product Picture
Figure United States Chronic Myelogenous Leukemia Treatment Market Size () by Application (2012-2022)
Figure United States Sales Market Share of Chronic Myelogenous Leukemia Treatment by Application in 2016
Figure Hospital Pharmacies Examples
Table Key Downstream Customer in Hospital Pharmacies
Figure Specialty Pharmacies Examples
Table Key Downstream Customer in Specialty Pharmacies
Figure Retail Pharmacies Examples
Table Key Downstream Customer in Retail Pharmacies
Figure United States Chronic Myelogenous Leukemia Treatment Market Size (Million USD) by Region (2012-2022)
Figure The West Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Chronic Myelogenous Leukemia Treatment Sales () and Growth Rate (2012-2022)
Figure United States Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Chronic Myelogenous Leukemia Treatment Market Major Players Product Sales Volume () (2012-2017)
Table United States Chronic Myelogenous Leukemia Treatment Sales () of Key Players/Suppliers (2012-2017)
Table United States Chronic Myelogenous Leukemia Treatment Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Chronic Myelogenous Leukemia Treatment Sales Share by Players/Suppliers
Figure 2017 United States Chronic Myelogenous Leukemia Treatment Sales Share by Players/Suppliers
Figure United States Chronic Myelogenous Leukemia Treatment Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Chronic Myelogenous Leukemia Treatment Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Chronic Myelogenous Leukemia Treatment Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Chronic Myelogenous Leukemia Treatment Revenue Share by Players/Suppliers
Figure 2017 United States Chronic Myelogenous Leukemia Treatment Revenue Share by Players/Suppliers
Table United States Market Chronic Myelogenous Leukemia Treatment Average Price () of Key Players/Suppliers (2012-2017)
Figure United States Market Chronic Myelogenous Leukemia Treatment Average Price () of Key Players/Suppliers in 2016
Figure United States Chronic Myelogenous Leukemia Treatment Market Share of Top 3 Players/Suppliers
Figure United States Chronic Myelogenous Leukemia Treatment Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Chronic Myelogenous Leukemia Treatment Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Chronic Myelogenous Leukemia Treatment Product Category
Table United States Chronic Myelogenous Leukemia Treatment Sales () by Region (2012-2017)
Table United States Chronic Myelogenous Leukemia Treatment Sales Share by Region (2012-2017)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Share by Region (2012-2017)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Market Share by Region in 2016
Table United States Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Chronic Myelogenous Leukemia Treatment Revenue Share by Region (2012-2017)
Figure United States Chronic Myelogenous Leukemia Treatment Revenue Market Share by Region (2012-2017)
Figure United States Chronic Myelogenous Leukemia Treatment Revenue Market Share by Region in 2016
Table United States Chronic Myelogenous Leukemia Treatment Price () by Region (2012-2017)
Table United States Chronic Myelogenous Leukemia Treatment Sales () by Type (2012-2017)
Table United States Chronic Myelogenous Leukemia Treatment Sales Share by Type (2012-2017)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Share by Type (2012-2017)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Market Share by Type in 2016
Table United States Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Chronic Myelogenous Leukemia Treatment Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Chronic Myelogenous Leukemia Treatment by Type (2012-2017)
Figure Revenue Market Share of Chronic Myelogenous Leukemia Treatment by Type in 2016
Table United States Chronic Myelogenous Leukemia Treatment Price () by Types (2012-2017)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Growth Rate by Type (2012-2017)
Table United States Chronic Myelogenous Leukemia Treatment Sales () by Application (2012-2017)
Table United States Chronic Myelogenous Leukemia Treatment Sales Market Share by Application (2012-2017)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Market Share by Application (2012-2017)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Market Share by Application in 2016
Table United States Chronic Myelogenous Leukemia Treatment Sales Growth Rate by Application (2012-2017)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Growth Rate by Application (2012-2017)
Table Bristol-Myers Squibb Basic Information List
Table Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Sales (), Revenue (Million USD), Price () and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Sales Growth Rate (2012-2017)
Figure Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Sales Market Share in United States (2012-2017)
Figure Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Revenue Market Share in United States (2012-2017)
Table Novartis AG Basic Information List
Table Novartis AG Chronic Myelogenous Leukemia Treatment Sales (), Revenue (Million USD), Price () and Gross Margin (2012-2017)
Figure Novartis AG Chronic Myelogenous Leukemia Treatment Sales Growth Rate (2012-2017)
Figure Novartis AG Chronic Myelogenous Leukemia Treatment Sales Market Share in United States (2012-2017)
Figure Novartis AG Chronic Myelogenous Leukemia Treatment Revenue Market Share in United States (2012-2017)
Table Pfizer Inc. Basic Information List
Table Pfizer Inc. Chronic Myelogenous Leukemia Treatment Sales (), Revenue (Million USD), Price () and Gross Margin (2012-2017)
Figure Pfizer Inc. Chronic Myelogenous Leukemia Treatment Sales Growth Rate (2012-2017)
Figure Pfizer Inc. Chronic Myelogenous Leukemia Treatment Sales Market Share in United States (2012-2017)
Figure Pfizer Inc. Chronic Myelogenous Leukemia Treatment Revenue Market Share in United States (2012-2017)
Table Teva Pharmaceuticals Basic Information List
Table Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Sales (), Revenue (Million USD), Price () and Gross Margin (2012-2017)
Figure Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Sales Growth Rate (2012-2017)
Figure Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Sales Market Share in United States (2012-2017)
Figure Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Revenue Market Share in United States (2012-2017)
Table Roche Holdings AG Basic Information List
Table Roche Holdings AG Chronic Myelogenous Leukemia Treatment Sales (), Revenue (Million USD), Price () and Gross Margin (2012-2017)
Figure Roche Holdings AG Chronic Myelogenous Leukemia Treatment Sales Growth Rate (2012-2017)
Figure Roche Holdings AG Chronic Myelogenous Leukemia Treatment Sales Market Share in United States (2012-2017)
Figure Roche Holdings AG Chronic Myelogenous Leukemia Treatment Revenue Market Share in United States (2012-2017)
Table Incyte Corporation Basic Information List
Table Incyte Corporation Chronic Myelogenous Leukemia Treatment Sales (), Revenue (Million USD), Price () and Gross Margin (2012-2017)
Figure Incyte Corporation Chronic Myelogenous Leukemia Treatment Sales Growth Rate (2012-2017)
Figure Incyte Corporation Chronic Myelogenous Leukemia Treatment Sales Market Share in United States (2012-2017)
Figure Incyte Corporation Chronic Myelogenous Leukemia Treatment Revenue Market Share in United States (2012-2017)
Table Bio-Path Holdings Basic Information List
Table Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Sales (), Revenue (Million USD), Price () and Gross Margin (2012-2017)
Figure Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Sales Growth Rate (2012-2017)
Figure Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Sales Market Share in United States (2012-2017)
Figure Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Chronic Myelogenous Leukemia Treatment
Figure Manufacturing Process Analysis of Chronic Myelogenous Leukemia Treatment
Figure Chronic Myelogenous Leukemia Treatment Industrial Chain Analysis
Table Raw Materials Sources of Chronic Myelogenous Leukemia Treatment Major Players/Suppliers in 2016
Table Major Buyers of Chronic Myelogenous Leukemia Treatment
Table Distributors/Traders List
Figure United States Chronic Myelogenous Leukemia Treatment Sales Volume () and Growth Rate Forecast (2017-2022)
Figure United States Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Chronic Myelogenous Leukemia Treatment Price () Trend Forecast (2017-2022)
Table United States Chronic Myelogenous Leukemia Treatment Sales Volume () Forecast by Type (2017-2022)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Volume () Forecast by Type (2017-2022)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Volume () Forecast by Type in 2022
Table United States Chronic Myelogenous Leukemia Treatment Sales Volume () Forecast by Application (2017-2022)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Volume () Forecast by Application (2017-2022)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Volume () Forecast by Application in 2022
Table United States Chronic Myelogenous Leukemia Treatment Sales Volume () Forecast by Region (2017-2022)
Table United States Chronic Myelogenous Leukemia Treatment Sales Volume Share Forecast by Region (2017-2022)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Volume Share Forecast by Region (2017-2022)
Figure United States Chronic Myelogenous Leukemia Treatment Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories